ClinicalTrials.gg
CompletedNCT00445432Updated Feb 2, 2012Results posted

A Study of Adalimumab for the Maintenance of Clinical Remission in Japanese Subjects With Crohn's Disease

A Phase 2/3 interventional study of adalimumab and Placebo in Crohn's Disease, sponsored by Abbott. Completed at 29 sites in Japan. Open to participants aged 15 Years to 75 Years. Per ClinicalTrials.gov, last updated 2012-02-02.

Sponsored by Abbott · Phase 2/3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2/3
Study type
Interventional
Enrollment
82
Allocation
Randomized
Ages
15 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 42 studies testing adalimumab in Crohn Disease — 4 open to participants now, 5 under way, none of them phase 3. Adalimumab · Crohn Disease.

Enrollment
29th of 42
82 · median 143
Started
2007
with 3 others
Phase 2/3
2 of 42
none open now
Registered
11th of 42
by date
Lead sponsor
13 of 42
Abbott

Among the 42 studies testing adalimumab in Crohn Disease, this one is the 29th largest by enrollment, is one of 4 that started in 2007, is one of 2 in phase 2/3, and was the 11th registered.

Crohn Disease

1,994 studies on the registry are indexed under Crohn Disease; 478 are open to participants now.

Browse Crohn Disease studies →

Open to participants now

4 of the 42 studies testing adalimumab in Crohn Disease are open now, in 5 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

About adalimumab

Adalimumab: first FDA approval 2002 (HUMIRA), first EMA approval 2003. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 353 Crohn Disease studies recruiting now, 154 (44%) set no upper age limit and 144 (41%) stop at 75 or younger; 95 take children under 18; 56 take healthy volunteers.

This study: 15 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 42 studies testing adalimumab in Crohn Disease, or all of them as a file.
02

Study summary

To demonstrate the efficacy and safety of adalimumab for the maintenance of clinical remission in Japanese subjects with Crohn's disease.

Read the detailed description

This was a Phase 2/3, multicenter, randomized, double-blind (DB), placebo-controlled, two-arm, efficacy, safety, and pharmacokinetic study designed to demonstrate the effectiveness of adalimumab in Japanese patients with moderate to severe Crohn's Disease (CD).

All participants who had completed Study M04-729 (NCT00445939), the lead-in adalimumab induction therapy study, were eligible for this study. Participants who rolled over into this study received either DB treatment (adalimumab or placebo) or open-label (OL) treatment with adalimumab.

Crohn's Disease Activity Index (CDAI) was used to determine participants who were responders and participants who were in clinical remission. CDAI documents number of soft stools, abdominal pain, general well-being, presence of 6 signs (arthritis/arthralgia; iritis/uveitis; erythema nodosum/pyoderma gangrenosum/aphthous stomatitis; fissure, abscess, anal fistula; other cutaneous fistula; fever over 100 degrees), taking medication for diarrhea, abdominal mass, hematocrit, and weight loss during a 1-week assessment period. It yields a total score >= 0 and without upper limit. Baseline scores in the study ranged from 221 to 448. Low score=less severe CD activity. Decrease in score indicates improvement.

Clinical remission is a CDAI score \< 150.

Clinical response-70 (CR-70) = decrease in CDAI ≥ 70 points from lead-in study Baseline score.

Clinical response-100 (CR-100) = decrease in CDAI ≥ 100 points from lead-in study Baseline score.

Participants who had CR-70 response at Week 4 of the induction study were randomized into 1 of 2 treatment groups (double-blind adalimumab 40 mg every other week or adalimumab placebo every other week) using 2 stratification factors - CDAI category (CDAI less than 150 and CDAI 150 or higher) and presence/absence of fistula at Week 0 of this study. The double-blind treatment was to last from Week 0 to Week 52. Any time at or after Week 4 of this study, if a participant's disease flared (defined as a recurrence of very active disease, specifically an increase in CDAI when compared to Week 0 in this study of ≥ 70 points and a CDAI above 220) during the double-blind treatment period, the participant was allowed to move to OL treatment. At Week 52, all participants still receiving DB treatment were to be moved to open-label treatment and could continue in the study until adalimumab is approved for commercial use in Japan.

Participants who did not respond by Week 4 in the induction study and participants who had disease flare during DB treatment of this study entered OL treatment and received adalimumab 40 mg every other week. At or after Week 4 of this study, if a participant in the open-label treatment group had a disease flare or if the participant was still not responding to treatment, the participant was allowed to dose escalate to adalimumab 80 mg every other week. Participants who entered open-label treatment were to be allowed to continue on open-label adalimumab until adalimumab is approved for commercial use in Japan.

The study is complete. Results of this study are reported for endpoints at Week 52 (end of the DB treatment period) for subjects who received DB treatment (adalimumab or placebo) or OL adalimumab treatment and for endpoints at Week 148 for all subjects who received at least one dose of adalimumab in this study.

03

Conditions studied

  • Crohn's Disease

Browse trials for

04

Who can participate

Ages eligible
15 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subjects who successfully enrolled in and completed the M04-729, (NCT00445939) study

Exclusion criteria

Exclusion Criteria:

  • Subject is considered by the investigator, for any reason, to be an unsuitable candidate for the study
05

Study design

Phase
Phase 2 / Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
82 participants (actual)

Study arms

  • Experimental
    DB Adalimumab 40 mg eow

    Subjects received double-blind (DB) 40 mg adalimumab subcutaneously (SC) every other week (eow) during the DB treatment period lasting 52 weeks.

    Biological: adalimumab

  • Placebo comparator
    Placebo eow

    Subjects received placebo subcutaneously (SC) every other week (eow) during the double-blind treatment period lasting 52 weeks.

    Other: Placebo

  • Experimental
    OL Adalimumab 40 mg eow

    Subjects received open-label (OL) 40 mg adalimumab subcutaneously (SC) every other week (eow) during the double-blind treatment period lasting 52 weeks.

    Biological: adalimumab

Interventions

  • Biologicaladalimumab

    Subcutaneous injection of 40 mg adalimumab (0.8 mL/injection) every other week (eow)

    Also known as: Humira, D2E7

  • OtherPlacebo

    Subcutaneous injection of placebo (0.8 mL/injection) every other week (eow)

06

What researchers measure

Primary outcomes

  1. Number of Participants Who Had Clinical Remission at Week 52 of Double-blind Treatment

    Clinical remission=Crohn's Disease (CD) Activity Index (CDAI) \<150; number of soft stools, abdominal pain, general well-being, presence of 6 signs (arthritis/arthralgia; iritis/uveitis; erythema nodosum/pyoderma gangrenosum/aphthous stomatitis; fissure, abscess, anal fistula; other cutaneous fistula; fever over 100 degrees), taking medication for diarrhea, abdominal mass, hematocrit, and weight loss are documented during 1-week assessment period. CDAI total score is \>= 0 and without upper limit. Low score=less severe CD activity. Decrease indicates improvement.

    Time frame: Week 52 of double-blind treatment

Secondary outcomes

  1. Number of Participants Who Had Clinical Response-70 (CR-70; a Decrease in Crohn's Disease Activity Index of at Least 70 Points From Lead-in Study [NCT00445939] Baseline Score) at Week 52 of Double-blind Treatment

    Crohn's Disease Activity Index (CDAI) documents number of soft stools, abdominal pain, general well-being, presence of 6 signs (arthritis/arthralgia; iritis/uveitis; erythema nodosum/pyoderma gangrenosum/aphthous stomatitis; fissure, abscess, anal fistula; other cutaneous fistula; fever over 100 degrees), taking medication for diarrhea, abdominal mass, hematocrit, and weight loss during a 1-week assessment period. CDAI has a total score \>= 0 and without upper limit. Low score=less severe CD activity. Decrease in score indicates improvement.

    Time frame: Week 52 of double-blind treatment

  2. Number of Participants Who Had Clinical Response-100 (CR-100; a Decrease in Crohn's Disease Activity Index of at Least 100 Points From Lead-in Study [NCT00445939] Baseline Score) at Week 52 of Double-blind Treatment

    Crohn's Disease Activity Index (CDAI) documents number of soft stools, abdominal pain, general well-being, presence of 6 signs (arthritis/arthralgia; iritis/uveitis; erythema nodosum/pyoderma gangrenosum/aphthous stomatitis; fissure, abscess, anal fistula; other cutaneous fistula; fever over 100 degrees), taking medication for diarrhea, abdominal mass, hematocrit, and weight loss during a 1-week assessment period. CDAI has a total score \>= 0 and without upper limit. Low score=less severe CD activity. Decrease in score indicates improvement.

    Time frame: Week 52 of double-blind treatment

  3. Change in Crohn's Disease Activity Index From Baseline of Lead-in Study (NCT00445939) to Week 52 of Double-blind Treatment

    Crohn's Disease Activity Index (CDAI) is a measure of disease severity. Number of soft stools, abdominal pain, general well-being, presence of 6 signs (arthritis/arthralgia; iritis/uveitis; erythema nodosum/pyoderma gangrenosum/aphthous stomatitis; fissure, abscess, anal fistula; other cutaneous fistula; fever over 100 degrees), taking medication for diarrhea, abdominal mass, hematocrit, and weight loss are documented during 1-week assessment period. CDAI has a total score \>= 0 and without upper limit. Low score=less severe CD activity. Decrease in score indicates improvement.

    Time frame: Baseline of lead-in study (NCT00445939) to Week 52 of double-blind treatment

  4. Number of Participants Who Had Clinical Remission at Week 52 of Open-label Treatment

    Clinical remission=Crohn's Disease (CD) Activity Index (CDAI) \<150; number of soft stools, abdominal pain, general well-being, presence of 6 signs (arthritis/arthralgia; iritis/uveitis; erythema nodosum/pyoderma gangrenosum/aphthous stomatitis; fissure, abscess, anal fistula; other cutaneous fistula; fever over 100 degrees), taking medication for diarrhea, abdominal mass, hematocrit, and weight loss are documented during 1-week assessment period. CDAI total score is \>= 0 and without upper limit. Low score=less severe CD activity. Decrease in score indicates improvement.

    Time frame: Week 52 of open-label treatment

  5. Change in International Organization for the Study of Inflammatory Bowel Disease (IOIBD) Score From Baseline of Lead-in Study (NCT00445939) to Week 52 of Double-blind Treatment

    The International Organization for the Study of Inflammatory Bowel Disease (IOIBD) score is an indicator of the activity of Crohn's disease. It measures absence (score of 0) or presence (score of 1) of abdominal pain, diarrhea or bloody stools more than 6 times per day, anal lesion, anal fistula, other complication, abdominal mass, weight loss, fever above 38 degrees Centigrade, abdominal tenderness, and blood pigment below 10 g/dL. Total possible score=0 to 10; low score=less disease activity. Decrease in score indicates alleviation of the disease; increase indicates aggravation of disease.

    Time frame: Baseline of lead-in study (NCT00445939) to Week 52 of double-blind treatment

  6. Change in Inflammatory Bowel Disease Questionnaire (IBDQ) From Baseline of Lead-in Study (NCT00445939) to Week 52 of Double-blind Treatment

    IBDQ is a validated disease-specific instrument that assesses the impact of IBD on patient quality of life during a 2-week recall period. It has 32 questions about bowel function and related symptoms, and their social and emotional impact. For each item, participants select 1 of 7 responses. 1=poor quality of life (e.g., feeling of fatigue "all of the time") and 7=good quality (e.g., feeling of fatigue "none of the time"). Scoring range = 32 to 224. Higher scores indicate better quality of life; increases in IBDQ = improved overall quality of life.

    Time frame: Baseline of lead-in study (NCT00445939) to Week 52 of double-blind treatment

  7. Change in Physical Component of the Short Form-36 Health Survey From Baseline of the Lead-in Study (NCT00445939) to Week 52 of Double-blind Treatment

    The Short-Form-36 (SF-36) Health Survey is a comprehensive quality of life scale. An increase in SF-36 score indicates alleviation of the disease and a decrease in score indicates aggravation of disease. The physical component reflects activity level, activity limitations, pain, and rating of one's health. Score on the physical component ranges from 0 (Poorest Health) to 100 (Best Health).

    Time frame: Baseline of lead-in study (NCT00445939) to Week 52 of double-blind treatment

  8. Change in Mental Component of the Short Form-36 Health Survey From Baseline of the Lead-in Study (NCT00445939) to Week 52 of Double-blind Treatment

    The Short-Form-36 (SF-36) Health Survey is a comprehensive quality of life scale. An increase in SF-36 score indicates alleviation of the disease and a decrease in score indicates aggravation. The mental component reflects energy/vitality, social functioning, limitations, and ratings of one's mental health. Score on mental component ranges from 0 (worst score) to 100 (best score).

    Time frame: Baseline of lead-in study (NCT00445939) to Week 52 of double-blind treatment

Other outcomes

  1. Number of Participants Who Had Clinical Remission at Week 148

    Clinical remission = Crohn's Disease (CD) Activity Index (CDAI) \<150; number of soft stools, abdominal pain, general well-being, presence of 6 signs (arthritis/arthralgia; iritis/uveitis; erythema nodosum/pyoderma gangrenosum/aphthous stomatitis; fissure, abscess, anal fistula; other cutaneous fistula; fever over 100 degrees), taking medication for diarrhea, abdominal mass, hematocrit, and weight loss are documented during 1-week assessment period. CDAI total score is \>= 0 and without upper limit. Low score=less severe CD activity. Decrease indicates improvement.

    Time frame: Week 148 relative to the first dose of adalimumab in NCT00445432 (Study M06-837)

  2. Number of Participants Who Had Clinical Response-70 (CR-70; a Decrease in Crohn's Disease Activity Index of at Least 70 Points From Lead-in Study [NCT00445939] Baseline Score) at Week 148

    Crohn's Disease Activity Index (CDAI) documents number of soft stools, abdominal pain, general well-being, presence of 6 signs (arthritis/arthralgia; iritis/uveitis; erythema nodosum/pyoderma gangrenosum/aphthous stomatitis; fissure, abscess, anal fistula; other cutaneous fistula; fever over 100 degrees), taking medication for diarrhea, abdominal mass, hematocrit, and weight loss during a 1-week assessment period. CDAI has a total score \>= 0 and without upper limit. Low score=less severe CD activity. Decrease in score indicates improvement.

    Time frame: Week 148 relative to the first dose of adalimumab in NCT00445432 (Study M06-837)

  3. Number of Participants Who Had Clinical Response-100 (CR-100; a Decrease in Crohn's Disease Activity Index of at Least 100 Points From Lead-in Study [NCT00445939] Baseline Score) at Week 148

    Crohn's Disease Activity Index (CDAI) documents number of soft stools, abdominal pain, general well-being, presence of 6 signs (arthritis/arthralgia; iritis/uveitis; erythema nodosum/pyoderma gangrenosum/aphthous stomatitis; fissure, abscess, anal fistula; other cutaneous fistula; fever over 100 degrees), taking medication for diarrhea, abdominal mass, hematocrit, and weight loss during a 1-week assessment period. CDAI has a total score \>= 0 and without upper limit. Low score=less severe CD activity. Decrease in score indicates improvement.

    Time frame: Week 148 relative to the first dose of adalimumab in NCT00445432 (Study M06-837)

  4. Change in Crohn's Disease Activity Index From Baseline of Lead-in Study (NCT00445939) to Week 148

    Crohn's Disease Activity Index (CDAI) is a measure of disease severity. Number of soft stools, abdominal pain, general well-being, presence of 6 signs (arthritis/arthralgia; iritis/uveitis; erythema nodosum/pyoderma gangrenosum/apthous stomatitis; fissure, abscess, anal fistula; other cutaneous fistula; fever over 100 degrees), taking medication for diarrhea, abdominal mass, hematocrit, and weight loss are documented during 1-week assessment period. CDAI has a total score \>=0 and without upper limit. Low score=less severe CD activity. Decrease in score indicates improvement.

    Time frame: Baseline of lead-in study (NCT00445939) to Week 148 relative to the first dose of adalimumab in NCT00445432 (Study M06-837)

  5. Change in International Organization for the Study of Inflammatory Bowel Disease (IOIBD) Score From Baseline of Lead-in Study (NCT00445939) to Week 148

    The International Organization for the Study of Inflammatory Bowel Disease (IOIBD) score is an indicator of the activity of Crohn's disease. It measures absence (score of 0) or presence (score of 1) of abdominal pain, diarrhea or bloody stools more than 6 times per day, anal lesion, anal fistula, other complication, abdominal mass, weight loss, fever above 38 degrees Centigrade, abdominal tenderness, and blood pigment below 10 g/dL. Total possible score=0 to 10; low score=less disease activity. Decrease in score indicates alleviation of the disease; increase indicates aggravation of disease.

    Time frame: Baseline of lead-in study (NCT00445939) to Week 148 relative to the first dose of adalimumab in NCT00445432 (Study M06-837)

  6. Change in Inflammatory Bowel Disease Questionnaire (IBDQ) From Baseline of Lead-in Study (NCT00445939) to Week 148

    IBDQ is a validated disease-specific instrument that assesses the impact of IBD on patient quality of life during a 2-week recall period with 32 questions about bowel function and related symptoms \& their social/emotional impact. Per item, participants select 1 of 7 responses (1=poor quality of life \[e.g., feeling of fatigue "all of the time"\]; 7=good quality \[e.g., feeling of fatigue "none of the time"\]). Scoring range=32 to 224. Higher scores indicate better quality of life; increases in IBDQ=improved overall quality of life.

    Time frame: Baseline of lead-in study (NCT00445939) to Week 148 relative to the first dose of adalimumab in NCT00445432 (Study M06-837)

  7. Change in Physical Component of the Short Form-36 Health Survey From Baseline of the Lead-in Study (NCT00445939) to Week 148

    The Short Form-36 (SF-36) Health Survey is a comprehensive quality of life scale. An increase in SF-36 score indicates alleviation of the disease and a decrease in score indicates aggravation of disease. The physical component reflects activity level, activity limitations, pain, and rating of one's health. Score on the physical component ranges from 0 to 100, with 0=Poorest Health and 100=Best Health.

    Time frame: Baseline of lead-in study (NCT00445939) to Week 148 relative to the first dose of adalimumab in NCT00445432 (Study M06-837)

  8. Change in Mental Component of the Short Form-36 Health Survey From Baseline of the Lead-in Study (NCT00445939) to Week 148

    The Short Form-36 (SF-36) Health Survey is a comprehensive quality of life scale. An increase in SF-36 indicates alleviation of the disease and a decrease in score indicates aggravation. The mental component reflects energy/vitality, social functioning, limitations, and ratings of one's mental health. Score on mental component ranges from 0 (worst score) to 100 (best score).

    Time frame: Baseline of lead-in study (NCT00445939) to Week 148 relative to the first dose of adalimumab in NCT00445432 (Study M06-837)

07

Results

Posted Jun 9, 2010

Participant flow

Through Week 52 of NCT00445432 (M06-837)
Participant flow — Through Week 52 of NCT00445432 (M06-837)
MilestoneDB Adalimumab 40 mg EowPlacebo EowOL Adalimumab 40 mg EowAny Adalimumab
Started2525320
Completed102210
Not completed1523110
Withdrew: Adverse event1270
Withdrew: Withdrawal by subject0020
Withdrew: Moved to open-label142000
Withdrew: Other0120
148 Weeks of Adalimumab Treatment
Participant flow — 148 Weeks of Adalimumab Treatment
MilestoneDB Adalimumab 40 mg EowPlacebo EowOL Adalimumab 40 mg EowAny Adalimumab
Started00079
Completed00035
Not completed00044
Withdrew: Adverse event00032
Withdrew: Withdrawal by subject0003
Withdrew: Other0009

Outcome measures

PrimaryNumber of Participants Who Had Clinical Remission at Week 52 of Double-blind Treatment

Clinical remission=Crohn's Disease (CD) Activity Index (CDAI) \<150; number of soft stools, abdominal pain, general well-being, presence of 6 signs (arthritis/arthralgia; iritis/uveitis; erythema nodosum/pyoderma gangrenosum/aphthous stomatitis; fissure, abscess, anal fistula; other cutaneous fistula; fever over 100 degrees), taking medication for diarrhea, abdominal mass, hematocrit, and weight loss are documented during 1-week assessment period. CDAI total score is \>= 0 and without upper limit. Low score=less severe CD activity. Decrease indicates improvement.

Time frame:
Week 52 of double-blind treatment
Reported as:
Number · Participants
Number of Participants Who Had Clinical Remission at Week 52 of Double-blind Treatment
ParticipantsDB Adalimumab 40 mg EowPlacebo Eow
Number of Participants Who Had Clinical Remission at Week 52 of Double-blind Treatment82
SecondaryNumber of Participants Who Had Clinical Response-70 (CR-70; a Decrease in Crohn's Disease Activity Index of at Least 70 Points From Lead-in Study [NCT00445939] Baseline Score) at Week 52 of Double-blind Treatment

Crohn's Disease Activity Index (CDAI) documents number of soft stools, abdominal pain, general well-being, presence of 6 signs (arthritis/arthralgia; iritis/uveitis; erythema nodosum/pyoderma gangrenosum/aphthous stomatitis; fissure, abscess, anal fistula; other cutaneous fistula; fever over 100 degrees), taking medication for diarrhea, abdominal mass, hematocrit, and weight loss during a 1-week assessment period. CDAI has a total score \>= 0 and without upper limit. Low score=less severe CD activity. Decrease in score indicates improvement.

Time frame:
Week 52 of double-blind treatment
Reported as:
Number · Participants
Number of Participants Who Had Clinical Response-70 (CR-70; a Decrease in Crohn's Disease Activity Index of at Least 70 Points From Lead-in Study [NCT00445939] Baseline Score) at Week 52 of Double-blind Treatment
ParticipantsDB Adalimumab 40 mg EowPlacebo EowOL Adalimumab 40 mg Eow
Number of Participants Who Had Clinical Response-70 (CR-70; a Decrease in Crohn's Disease Activity Index of at Least 70 Points From Lead-in Study [NCT00445939] Baseline Score) at Week 52 of Double-blind Treatment9210
SecondaryNumber of Participants Who Had Clinical Response-100 (CR-100; a Decrease in Crohn's Disease Activity Index of at Least 100 Points From Lead-in Study [NCT00445939] Baseline Score) at Week 52 of Double-blind Treatment

Crohn's Disease Activity Index (CDAI) documents number of soft stools, abdominal pain, general well-being, presence of 6 signs (arthritis/arthralgia; iritis/uveitis; erythema nodosum/pyoderma gangrenosum/aphthous stomatitis; fissure, abscess, anal fistula; other cutaneous fistula; fever over 100 degrees), taking medication for diarrhea, abdominal mass, hematocrit, and weight loss during a 1-week assessment period. CDAI has a total score \>= 0 and without upper limit. Low score=less severe CD activity. Decrease in score indicates improvement.

Time frame:
Week 52 of double-blind treatment
Reported as:
Number · Participants
Number of Participants Who Had Clinical Response-100 (CR-100; a Decrease in Crohn's Disease Activity Index of at Least 100 Points From Lead-in Study [NCT00445939] Baseline Score) at Week 52 of Double-blind Treatment
ParticipantsDB Adalimumab 40 mg EowPlacebo EowOL Adalimumab 40 mg Eow
Number of Participants Who Had Clinical Response-100 (CR-100; a Decrease in Crohn's Disease Activity Index of at Least 100 Points From Lead-in Study [NCT00445939] Baseline Score) at Week 52 of Double-blind Treatment828
SecondaryChange in Crohn's Disease Activity Index From Baseline of Lead-in Study (NCT00445939) to Week 52 of Double-blind Treatment

Crohn's Disease Activity Index (CDAI) is a measure of disease severity. Number of soft stools, abdominal pain, general well-being, presence of 6 signs (arthritis/arthralgia; iritis/uveitis; erythema nodosum/pyoderma gangrenosum/aphthous stomatitis; fissure, abscess, anal fistula; other cutaneous fistula; fever over 100 degrees), taking medication for diarrhea, abdominal mass, hematocrit, and weight loss are documented during 1-week assessment period. CDAI has a total score \>= 0 and without upper limit. Low score=less severe CD activity. Decrease in score indicates improvement.

Time frame:
Baseline of lead-in study (NCT00445939) to Week 52 of double-blind treatment
Reported as:
Mean · units on a scale
Change in Crohn's Disease Activity Index From Baseline of Lead-in Study (NCT00445939) to Week 52 of Double-blind Treatment
units on a scaleDB Adalimumab 40 mg EowPlacebo Eow
Change in Crohn's Disease Activity Index From Baseline of Lead-in Study (NCT00445939) to Week 52 of Double-blind Treatment-83.7 ± 110.26-9.1 ± 110.41
SecondaryNumber of Participants Who Had Clinical Remission at Week 52 of Open-label Treatment

Clinical remission=Crohn's Disease (CD) Activity Index (CDAI) \<150; number of soft stools, abdominal pain, general well-being, presence of 6 signs (arthritis/arthralgia; iritis/uveitis; erythema nodosum/pyoderma gangrenosum/aphthous stomatitis; fissure, abscess, anal fistula; other cutaneous fistula; fever over 100 degrees), taking medication for diarrhea, abdominal mass, hematocrit, and weight loss are documented during 1-week assessment period. CDAI total score is \>= 0 and without upper limit. Low score=less severe CD activity. Decrease in score indicates improvement.

Time frame:
Week 52 of open-label treatment
Reported as:
Number · Participants
Number of Participants Who Had Clinical Remission at Week 52 of Open-label Treatment
ParticipantsOL Adalimumab 40 mg Eow
Number of Participants Who Had Clinical Remission at Week 52 of Open-label Treatment5
SecondaryChange in International Organization for the Study of Inflammatory Bowel Disease (IOIBD) Score From Baseline of Lead-in Study (NCT00445939) to Week 52 of Double-blind Treatment

The International Organization for the Study of Inflammatory Bowel Disease (IOIBD) score is an indicator of the activity of Crohn's disease. It measures absence (score of 0) or presence (score of 1) of abdominal pain, diarrhea or bloody stools more than 6 times per day, anal lesion, anal fistula, other complication, abdominal mass, weight loss, fever above 38 degrees Centigrade, abdominal tenderness, and blood pigment below 10 g/dL. Total possible score=0 to 10; low score=less disease activity. Decrease in score indicates alleviation of the disease; increase indicates aggravation of disease.

Time frame:
Baseline of lead-in study (NCT00445939) to Week 52 of double-blind treatment
Reported as:
Mean · units on a scale
Change in International Organization for the Study of Inflammatory Bowel Disease (IOIBD) Score From Baseline of Lead-in Study (NCT00445939) to Week 52 of Double-blind Treatment
units on a scaleDB Adalimumab 40 mg EowPlacebo Eow
Change in International Organization for the Study of Inflammatory Bowel Disease (IOIBD) Score From Baseline of Lead-in Study (NCT00445939) to Week 52 of Double-blind Treatment-0.8 ± 1.89-0.2 ± 1.34
SecondaryChange in Inflammatory Bowel Disease Questionnaire (IBDQ) From Baseline of Lead-in Study (NCT00445939) to Week 52 of Double-blind Treatment

IBDQ is a validated disease-specific instrument that assesses the impact of IBD on patient quality of life during a 2-week recall period. It has 32 questions about bowel function and related symptoms, and their social and emotional impact. For each item, participants select 1 of 7 responses. 1=poor quality of life (e.g., feeling of fatigue "all of the time") and 7=good quality (e.g., feeling of fatigue "none of the time"). Scoring range = 32 to 224. Higher scores indicate better quality of life; increases in IBDQ = improved overall quality of life.

Time frame:
Baseline of lead-in study (NCT00445939) to Week 52 of double-blind treatment
Reported as:
Mean · units on a scale
Change in Inflammatory Bowel Disease Questionnaire (IBDQ) From Baseline of Lead-in Study (NCT00445939) to Week 52 of Double-blind Treatment
units on a scaleDB Adalimumab 40 mg EowPlacebo Eow
Change in Inflammatory Bowel Disease Questionnaire (IBDQ) From Baseline of Lead-in Study (NCT00445939) to Week 52 of Double-blind Treatment27.8 ± 32.441.8 ± 35.42
SecondaryChange in Physical Component of the Short Form-36 Health Survey From Baseline of the Lead-in Study (NCT00445939) to Week 52 of Double-blind Treatment

The Short-Form-36 (SF-36) Health Survey is a comprehensive quality of life scale. An increase in SF-36 score indicates alleviation of the disease and a decrease in score indicates aggravation of disease. The physical component reflects activity level, activity limitations, pain, and rating of one's health. Score on the physical component ranges from 0 (Poorest Health) to 100 (Best Health).

Time frame:
Baseline of lead-in study (NCT00445939) to Week 52 of double-blind treatment
Reported as:
Mean · units on a scale
Change in Physical Component of the Short Form-36 Health Survey From Baseline of the Lead-in Study (NCT00445939) to Week 52 of Double-blind Treatment
units on a scaleDB Adalimumab 40 mg EowPlacebo Eow
Change in Physical Component of the Short Form-36 Health Survey From Baseline of the Lead-in Study (NCT00445939) to Week 52 of Double-blind Treatment4.4 ± 9.090.2 ± 6.31
SecondaryChange in Mental Component of the Short Form-36 Health Survey From Baseline of the Lead-in Study (NCT00445939) to Week 52 of Double-blind Treatment

The Short-Form-36 (SF-36) Health Survey is a comprehensive quality of life scale. An increase in SF-36 score indicates alleviation of the disease and a decrease in score indicates aggravation. The mental component reflects energy/vitality, social functioning, limitations, and ratings of one's mental health. Score on mental component ranges from 0 (worst score) to 100 (best score).

Time frame:
Baseline of lead-in study (NCT00445939) to Week 52 of double-blind treatment
Reported as:
Mean · units on a scale
Change in Mental Component of the Short Form-36 Health Survey From Baseline of the Lead-in Study (NCT00445939) to Week 52 of Double-blind Treatment
units on a scaleDB Adalimumab 40 mg EowPlacebo Eow
Change in Mental Component of the Short Form-36 Health Survey From Baseline of the Lead-in Study (NCT00445939) to Week 52 of Double-blind Treatment9.6 ± 8.370.3 ± 14.15
Other pre-specifiedNumber of Participants Who Had Clinical Remission at Week 148

Clinical remission = Crohn's Disease (CD) Activity Index (CDAI) \<150; number of soft stools, abdominal pain, general well-being, presence of 6 signs (arthritis/arthralgia; iritis/uveitis; erythema nodosum/pyoderma gangrenosum/aphthous stomatitis; fissure, abscess, anal fistula; other cutaneous fistula; fever over 100 degrees), taking medication for diarrhea, abdominal mass, hematocrit, and weight loss are documented during 1-week assessment period. CDAI total score is \>= 0 and without upper limit. Low score=less severe CD activity. Decrease indicates improvement.

Time frame:
Week 148 relative to the first dose of adalimumab in NCT00445432 (Study M06-837)
Reported as:
Number · participants
Number of Participants Who Had Clinical Remission at Week 148
participantsAny Adalimumab
Number of Participants Who Had Clinical Remission at Week 14821
Other pre-specifiedNumber of Participants Who Had Clinical Response-70 (CR-70; a Decrease in Crohn's Disease Activity Index of at Least 70 Points From Lead-in Study [NCT00445939] Baseline Score) at Week 148

Crohn's Disease Activity Index (CDAI) documents number of soft stools, abdominal pain, general well-being, presence of 6 signs (arthritis/arthralgia; iritis/uveitis; erythema nodosum/pyoderma gangrenosum/aphthous stomatitis; fissure, abscess, anal fistula; other cutaneous fistula; fever over 100 degrees), taking medication for diarrhea, abdominal mass, hematocrit, and weight loss during a 1-week assessment period. CDAI has a total score \>= 0 and without upper limit. Low score=less severe CD activity. Decrease in score indicates improvement.

Time frame:
Week 148 relative to the first dose of adalimumab in NCT00445432 (Study M06-837)
Reported as:
Number · participants
Number of Participants Who Had Clinical Response-70 (CR-70; a Decrease in Crohn's Disease Activity Index of at Least 70 Points From Lead-in Study [NCT00445939] Baseline Score) at Week 148
participantsAny Adalimumab
Number of Participants Who Had Clinical Response-70 (CR-70; a Decrease in Crohn's Disease Activity Index of at Least 70 Points From Lead-in Study [NCT00445939] Baseline Score) at Week 14828
Other pre-specifiedNumber of Participants Who Had Clinical Response-100 (CR-100; a Decrease in Crohn's Disease Activity Index of at Least 100 Points From Lead-in Study [NCT00445939] Baseline Score) at Week 148

Crohn's Disease Activity Index (CDAI) documents number of soft stools, abdominal pain, general well-being, presence of 6 signs (arthritis/arthralgia; iritis/uveitis; erythema nodosum/pyoderma gangrenosum/aphthous stomatitis; fissure, abscess, anal fistula; other cutaneous fistula; fever over 100 degrees), taking medication for diarrhea, abdominal mass, hematocrit, and weight loss during a 1-week assessment period. CDAI has a total score \>= 0 and without upper limit. Low score=less severe CD activity. Decrease in score indicates improvement.

Time frame:
Week 148 relative to the first dose of adalimumab in NCT00445432 (Study M06-837)
Reported as:
Number · participants
Number of Participants Who Had Clinical Response-100 (CR-100; a Decrease in Crohn's Disease Activity Index of at Least 100 Points From Lead-in Study [NCT00445939] Baseline Score) at Week 148
participantsAny Adalimumab
Number of Participants Who Had Clinical Response-100 (CR-100; a Decrease in Crohn's Disease Activity Index of at Least 100 Points From Lead-in Study [NCT00445939] Baseline Score) at Week 14826
Other pre-specifiedChange in Crohn's Disease Activity Index From Baseline of Lead-in Study (NCT00445939) to Week 148

Crohn's Disease Activity Index (CDAI) is a measure of disease severity. Number of soft stools, abdominal pain, general well-being, presence of 6 signs (arthritis/arthralgia; iritis/uveitis; erythema nodosum/pyoderma gangrenosum/apthous stomatitis; fissure, abscess, anal fistula; other cutaneous fistula; fever over 100 degrees), taking medication for diarrhea, abdominal mass, hematocrit, and weight loss are documented during 1-week assessment period. CDAI has a total score \>=0 and without upper limit. Low score=less severe CD activity. Decrease in score indicates improvement.

Time frame:
Baseline of lead-in study (NCT00445939) to Week 148 relative to the first dose of adalimumab in NCT00445432 (Study M06-837)
Reported as:
Mean · units on a scale
Change in Crohn's Disease Activity Index From Baseline of Lead-in Study (NCT00445939) to Week 148
units on a scaleAny Adalimumab
Change in Crohn's Disease Activity Index From Baseline of Lead-in Study (NCT00445939) to Week 148-143.0 ± 102.49
Other pre-specifiedChange in International Organization for the Study of Inflammatory Bowel Disease (IOIBD) Score From Baseline of Lead-in Study (NCT00445939) to Week 148

The International Organization for the Study of Inflammatory Bowel Disease (IOIBD) score is an indicator of the activity of Crohn's disease. It measures absence (score of 0) or presence (score of 1) of abdominal pain, diarrhea or bloody stools more than 6 times per day, anal lesion, anal fistula, other complication, abdominal mass, weight loss, fever above 38 degrees Centigrade, abdominal tenderness, and blood pigment below 10 g/dL. Total possible score=0 to 10; low score=less disease activity. Decrease in score indicates alleviation of the disease; increase indicates aggravation of disease.

Time frame:
Baseline of lead-in study (NCT00445939) to Week 148 relative to the first dose of adalimumab in NCT00445432 (Study M06-837)
Reported as:
Mean · units on a scale
Change in International Organization for the Study of Inflammatory Bowel Disease (IOIBD) Score From Baseline of Lead-in Study (NCT00445939) to Week 148
units on a scaleAny Adalimumab
Change in International Organization for the Study of Inflammatory Bowel Disease (IOIBD) Score From Baseline of Lead-in Study (NCT00445939) to Week 148-1.7 ± 1.41
Other pre-specifiedChange in Inflammatory Bowel Disease Questionnaire (IBDQ) From Baseline of Lead-in Study (NCT00445939) to Week 148

IBDQ is a validated disease-specific instrument that assesses the impact of IBD on patient quality of life during a 2-week recall period with 32 questions about bowel function and related symptoms \& their social/emotional impact. Per item, participants select 1 of 7 responses (1=poor quality of life \[e.g., feeling of fatigue "all of the time"\]; 7=good quality \[e.g., feeling of fatigue "none of the time"\]). Scoring range=32 to 224. Higher scores indicate better quality of life; increases in IBDQ=improved overall quality of life.

Time frame:
Baseline of lead-in study (NCT00445939) to Week 148 relative to the first dose of adalimumab in NCT00445432 (Study M06-837)
Reported as:
Mean · units on a scale
Change in Inflammatory Bowel Disease Questionnaire (IBDQ) From Baseline of Lead-in Study (NCT00445939) to Week 148
units on a scaleAny Adalimumab
Change in Inflammatory Bowel Disease Questionnaire (IBDQ) From Baseline of Lead-in Study (NCT00445939) to Week 14827.2 ± 31.22
Other pre-specifiedChange in Physical Component of the Short Form-36 Health Survey From Baseline of the Lead-in Study (NCT00445939) to Week 148

The Short Form-36 (SF-36) Health Survey is a comprehensive quality of life scale. An increase in SF-36 score indicates alleviation of the disease and a decrease in score indicates aggravation of disease. The physical component reflects activity level, activity limitations, pain, and rating of one's health. Score on the physical component ranges from 0 to 100, with 0=Poorest Health and 100=Best Health.

Time frame:
Baseline of lead-in study (NCT00445939) to Week 148 relative to the first dose of adalimumab in NCT00445432 (Study M06-837)
Reported as:
Mean · units on a scale
Change in Physical Component of the Short Form-36 Health Survey From Baseline of the Lead-in Study (NCT00445939) to Week 148
units on a scaleAny Adalimumab
Change in Physical Component of the Short Form-36 Health Survey From Baseline of the Lead-in Study (NCT00445939) to Week 1485.44 ± 7.245
Other pre-specifiedChange in Mental Component of the Short Form-36 Health Survey From Baseline of the Lead-in Study (NCT00445939) to Week 148

The Short Form-36 (SF-36) Health Survey is a comprehensive quality of life scale. An increase in SF-36 indicates alleviation of the disease and a decrease in score indicates aggravation. The mental component reflects energy/vitality, social functioning, limitations, and ratings of one's mental health. Score on mental component ranges from 0 (worst score) to 100 (best score).

Time frame:
Baseline of lead-in study (NCT00445939) to Week 148 relative to the first dose of adalimumab in NCT00445432 (Study M06-837)
Reported as:
Mean · units on a scale
Change in Mental Component of the Short Form-36 Health Survey From Baseline of the Lead-in Study (NCT00445939) to Week 148
units on a scaleAny Adalimumab
Change in Mental Component of the Short Form-36 Health Survey From Baseline of the Lead-in Study (NCT00445939) to Week 1486.44 ± 11.173

Adverse events

Collected over 52 weeks for the double-blind (DB) treatments (adalimumab and placebo) and for the open-label adalimumab treatment. Overall study (maximum adalimumab treatment of 184 weeks plus 70-day follow-up period) for the Any Adalimumab group.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
DB Adalimumab 40 mg Eow—2/25 (8%)17/25 (68%)
Placebo Eow—6/25 (24%)13/25 (52%)
OL Adalimumab 40 mg Eow—13/32 (40.6%)28/32 (87.5%)
Any Adalimumab—49/79 (62%)73/79 (92.4%)
Most frequent serious events
Showing 10 of 44
Most frequent serious events
EventDB Adalimumab 40 mg EowPlacebo EowOL Adalimumab 40 mg EowAny Adalimumab
Crohn's diseaseGastrointestinal disorders1/253/259/3226/79
Abdominal abscessInfections and infestations1/250/250/324/79
IleusGastrointestinal disorders0/250/250/324/79
Intestinal obstructionGastrointestinal disorders1/250/251/323/79
Intestinal perforationGastrointestinal disorders0/251/250/322/79
SubileusGastrointestinal disorders0/251/250/320/79
Liver abscessInfections and infestations0/251/250/320/79
Perianal abscessInfections and infestations0/251/250/321/79
SomnolenceNervous system disorders0/251/250/320/79
PeritonitisGastrointestinal disorders0/250/250/323/79
Most frequent other events
Showing 10 of 51
Most frequent other events
EventDB Adalimumab 40 mg EowPlacebo EowOL Adalimumab 40 mg EowAny Adalimumab
NasopharyngitisInfections and infestations14/253/2523/3260/79
Adverse drug reactionGeneral disorders3/251/256/3222/79
PyrexiaGeneral disorders2/251/253/3217/79
Dental cariesGastrointestinal disorders3/251/253/3216/79
HeadacheNervous system disorders1/252/254/3216/79
Crohn's diseaseGastrointestinal disorders2/254/254/3215/79
Iron deficiency anaemiaBlood and lymphatic system disorders0/250/256/3212/79
RhinorrhoeaRespiratory, thoracic and mediastinal disorders4/250/250/328/79
Pharyngolaryngeal painRespiratory, thoracic and mediastinal disorders0/250/254/3211/79
InsomniaPsychiatric disorders0/250/250/3210/79

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)DB Adalimumab 40 mg EowPlacebo EowOL Adalimumab 40 mg EowTotal
<=18 years0235
Between 18 and 65 years25232977
>=65 years0000
Age Continuous
Age Continuous(years)DB Adalimumab 40 mg EowPlacebo EowOL Adalimumab 40 mg EowTotal
Mean31.60 ± 7.17130.80 ± 10.93930.75 ± 8.35931.02 ± 8.808
Sex: Female, Male
Sex: Female, Male(Participants)DB Adalimumab 40 mg EowPlacebo EowOL Adalimumab 40 mg EowTotal
Female9101433
Male16151849
Region of Enrollment
Region of Enrollment(participants)DB Adalimumab 40 mg EowPlacebo EowOL Adalimumab 40 mg EowTotal
Japan25253282
08

Study locations

29 sites
  • Site Ref # / Investigator 46965
    Aichi, Japan
  • Site Ref # / Investigator 46977
    Aichi, Japan
  • Site Ref # / Investigator 46978
    Aichi, Japan
  • Site Ref # / Investigator 46979
    Aichi, Japan
  • Site Ref # / Investigator 46922
    Chiba, Japan
  • Site Ref # / Investigator 46974
    Chiba, Japan
  • Site Ref # / Investigator 46970
    Ehime, Japan
  • Site Ref # / Investigator 46971
    Fukuoka, Japan
  • Site Ref # / Investigator 46985
    Fukuoka, Japan
  • Site Ref # / Investigator 46986
    Fukuoka, Japan
  • Site Ref # / Investigator 46987
    Fukuoka, Japan
  • Site Ref # / Investigator 46968
    Hiroshima, Japan
  • Site Ref # / Investigator 46973
    Hokkaido, Japan
  • Site Ref # / Investigator 6881
    Hokkaido, Japan
  • Site Ref # / Investigator 46982
    Hyogo, Japan
  • Site Ref # / Investigator 46969
    Kagawa, Japan
  • Site Ref # / Investigator 46927
    Kanagawa, Japan
  • Site Ref # / Investigator 46984
    Kochi, Japan
  • Site Ref # / Investigator 46981
    Kyoto, Japan
  • Site Ref # / Investigator 46921
    Miyagi, Japan
  • Site Ref # / Investigator 46983
    Okayama, Japan
  • Site Ref # / Investigator 46966
    Osaka, Japan
  • Site Ref # / Investigator 46967
    Osaka, Japan
  • Site Ref # / Investigator 46980
    Shiga, Japan
  • Site Ref # / Investigator 46964
    Shizuoka, Japan
  • Site Ref # / Investigator 46923
    Tokyo, Japan
  • Site Ref # / Investigator 46924
    Tokyo, Japan
  • Site Ref # / Investigator 46975
    Tokyo, Japan
  • Site Ref # / Investigator 46976
    Tokyo, Japan
09

References and documents

Publications

  • Watanabe M, Hibi T, Mostafa NM, Chao J, Arora V, Camez A, Petersson J, Thakkar R. Long-term safety and efficacy of adalimumab in Japanese patients with moderate to severe Crohn's disease. J Crohns Colitis. 2014 Nov;8(11):1407-16. doi: 10.1016/j.crohns.2014.04.012. Epub 2014 May 27. PubMed 24874893 ↗
  • Watanabe M, Hibi T, Lomax KG, Paulson SK, Chao J, Alam MS, Camez A; Study Investigators. Adalimumab for the induction and maintenance of clinical remission in Japanese patients with Crohn's disease. J Crohns Colitis. 2012 Mar;6(2):160-73. doi: 10.1016/j.crohns.2011.07.013. Epub 2011 Aug 26. PubMed 22325170 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Mar 2007, a primary completion of Mar 2009 and a completion of Nov 2010. It does not say whether these dates are actual or estimated.

Results were first posted in Jun 2010, 1 year 3 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 7, 2007
First posted
Mar 9, 2007
Start
Mar 2007
Primary completionActual
Mar 2009
CompletionActual
Nov 2010
Results first posted
Jun 9, 2010
Last update
Feb 2, 2012
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 2, 2012, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00445432
Lead sponsor
Abbott
Collaborators
Eisai Co., Ltd.
Responsible party
Sponsor
First posted
Mar 9, 2007
Start date
Mar 2007
Primary completion
Mar 2009
Completion
Nov 2010
Results posted
Jun 9, 2010
Last update
Feb 2, 2012

Study contacts

Kazuko Kobayashi
study director · Abbott
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2012. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Adalimumab

Start the discussion